MCL1 and acute myeloid leukemia: In contrast to venetoclax, the MCL1 inhibitor S6384523, which also holds promise as an AML therapeutic, exhibited efficacy even at a concentration as low as 0.01 μM, profoundly suppressing cell viability in a dose-dependent manner.